News | August 09, 2025
Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Subscribe To Our Newsletter & Stay Updated
